Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

“…Regarding staging, 18 patients (35%) were included with stage IIIB disease and 34 patients (65%) with stage IV. The patients with progressive dispnea (15 patients) also received palliative doses of radiotherapy (30)(31)(32)(33)(34)(35)(36) to the tumoral region and/or mediastinum in Kocaeli University, Radiation Oncology Department. The patient characteristics are shown in Table 1.…”

“…The one-year survival rate was 28%. Hematologic toxicity rate was moderate with an amount of Grade 3-4 neutropenia of 53% (30% Grade 4) and 14% of patients experienced febrile neutropenia [31].…”

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

“…The DISTAL-2 trial will compare weekly docetaxel with combinations of weekly docetaxel plus capecitabine (Nadella et al, 2002), vinorelbine Leu et al, 2001) and gemcitabine (Kosmas et al, 2001;Spiridonidis et al, 2001); for this trial the DISTAL Investigators agreed to apply a slightly modified schedule of docetaxel (i.e. treatment for 3 consecutive weeks followed by 1 week of rest) that should be equivalent to the one studied in the DISTAL-1 trial, but more easy to combine with other cytotoxic agents.…”

Second-line treatment for advanced non-small cell lung cancer: A systematic review

“…Among these phase II studies, both platinum-based [24][25][26][27][28][29][30][31][32][33][34][35] and non-platinum [36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55] regimens were used (Tables 3 and 4). Four randomized studies compared a single-agent chemotherapy versus a two-drugs regimen [56][57][58][59] (Table 5).…”